On tolerability and safety of a maintenance treatment with 6-thioguanine in azathioprine or 6-mercaptopurine intolerant IBD patients

World Journal of Gastroenterology

Volumn 11, Issue 35, 2005, Pages 5541-5544

  de Boer, Nanne K H ^a   Derijks, Luc J J ^b   Gilissen, Lennard P L ^c   Hommes, Daniel W ^d   Engels, Leopold G J B ^e   de Boer, Sybrand Y ^f   den Hartog, Gijsbertus ^f   Hooymans, Piet M ^e   Mäkelburg, Anja B U ^g   Westerveld, Barend D ^g   Naber, Anton H J ^h   Mulder, Chris J J ^a   de Jong, Dirk J ^h  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b MÁXIMA MEDICAL CENTER   (Netherlands)

^c MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^d ACADEMIC MEDICAL CENTER   (Netherlands)

^e Sittard Geleen Heerlen   (Netherlands)

^f RIJNSTATE HOSPITAL   (Netherlands)

^g ISALA HOSPITAL   (Netherlands)

^h RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

6 Mercaptopurine; 6 Thioguanine; Azathioprine; Crohn's disease; Safety; Side effects; Tolerance; Ulcerative colitis

Indexed keywords

AZATHIOPRINE; DRUG METABOLITE; IMMUNOSUPPRESSIVE AGENT; MERCAPTOPURINE; TIOGUANINE;

ADULT; AGED; ALOPECIA; ARTICLE; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; CLINICAL STUDY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; ENTERITIS; FEMALE; GALLBLADDER DISEASE; GASTROINTESTINAL SYMPTOM; HEMATOLOGIC DISEASE; HUMAN; LEUKOPENIA; LIVER TOXICITY; LOW DRUG DOSE; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALAISE; MALE; MYALGIA; PANCREAS DISEASE; SPLENOMEGALY; THROMBOCYTOPENIA; DRUG TOLERANCE; METABOLISM; MIDDLE AGED; RETROSPECTIVE STUDY; SAFETY;

6-MERCAPTOPURINE; ADULT; AGED; AZATHIOPRINE; DRUG TOLERANCE; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATORY BOWEL DISEASES; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SAFETY; THIOGUANINE;

EID: 28044472012     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Sandborn WJ. A review of immune modifier therapy for inflammatory bowel disease: azathioprine, 6-mercaptopurine, cyclosporine, and methotrexate. Am J Gastroenterol 1996; 91: 423-433
2. Present DH, Meltzer SJ, Krumholz MP, Wolke A, Korelitz BI. 6-Mercaptopurine in the management of inflammatory bowel disease: short- and long-term toxicity. Ann Intern Med 1989; 111: 641-649
3. Dubinsky MC, Lamothe S, Yang HY, Targan SR, Sinnett D, Theoret Y, Seidman EG. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology 2000; 118: 705-713
4. Marinaki AM, Ansari A, Duley JA, Arenas M, Sumi S, Lewis CM, Shobowale-Bakre E, Escuredo E, Fairbanks LD, Sanderson JD. Adverse drug reactions to azathioprine therapy are associated with polymorphism in the gene encoding inosine triphosphate pyrophosphatase (ITPase). Pharmacogenetics 2004; 14: 181-187
5. De Jong D, Mulder CJ, van Sorge AA. Why measure thiopurine methyltransferase activity? Direct administration of 6-thioguanine might be the alternative for 6-mercaptopurine or azathioprine. Gut 2001; 49: 874
6. Derijks LJ, de Jong DJ, Gilissen LP, Engels LG, Hooymans PM, Jansen JB, Mulder CJ. 6-Thioguanine seems promising in azathioprine- or 6-mercaptopurine-intolerant inflammatory bowel disease patients: a short-term safety assessment. Eur J Gastroenterol Hepatol 2003; 15: 63-67
7. Dubinsky MC, Feldman EJ, Abreu MT, Targan SR, Vasiliauskas EA. Thioguanine: a potential alternate thiopurine for IBD patients allergic to 6-mercaptopurine or azathioprine. Am J Gastroenterol 2003; 98: 1058-1063
8. Derijks LJ, Gilissen LP, Engels LG, Bos LP, Bus PJ, Lohman JJ, Curvers WL, Van Deventer SJ, Hommes DW, Hooymans PM. Pharmacokinetics of 6-mercaptopurine in patients with inflammatory bowel disease: implications for therapy. Ther Drug Monit 2004; 26: 311-318
9. Cuffari C, Hunt S, Bayless T. Utilisation of erythrocyte 6-thioguanine metabolite levels to optimise azathioprine therapy in patients with inflammatory bowel disease. Gut 2001; 48: 642-646
10. Ansari A, Hassan C, Duley J, Marinaki A, Shobowale-Bakre EM, Seed P, Meenan J, Yim A, Sanderson J. Thiopurine methyltransferase activity and the use of azathioprine in inflammatory bowel disease. Aliment Pharmacol Ther 2002; 16: 1743-1750
11. Weinshilboum R. Thiopurine pharmacogenetics: clinical and molecular studies of thiopurine methyltransferase. Drug Metab Dispos 2001; 29: 601-605
12. Dubinsky MC, Vasiliauskas EA, Singh H, Abreu MT, Papadakis KA, Tran T, Martin P, Vierling JM, Geller SA, Targan SR, Poordad FF. 6-thioguanine can cause serious liver injury in inflammatory bowel disease patients. Gastroenterology 2003; 125: 298-303
13. Ardizzone S, Bollani S, Manzionna G, Imbesi V, Colombo E, Bianchi PG. Comparison between methotrexate and azathioprine in the treatment of chronic active Crohn's disease: a randomised, investigator-blind study. Dig Liver Dis 2003; 35: 619-627
14. Bell SJ, Kamm MA. Review article: the clinical role of anti-TNFalpha antibody treatment in Crohn's disease. Aliment Pharmacol Ther 2000; 14: 501-514
15. Hanauer SB, Present DH. The state of the art in the management of inflammatory bowel disease. Rev Gastroenterol Disord 2003; 3: 81-92
16. Rutgeerts P, Van Assche G, Vermeire S. Optimizing anti-TNF treatment in inflammatory bowel disease. Gastroenterology 2004; 126: 1593-1610